Cabaletta Bio, Inc. — Form 10-Q Summary
Business context and reporting period
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies for autoimmune diseases through its CABA platform, including CAR T and CAAR T approaches. The filing covers the three and nine months ended September 30, 2023, and was filed November 9, 2023. The company had 42,849,412 common shares outstanding as of November 3, 2023.
- Lead programs include CABA-201, DSG3-CAART and MuSK-CAART.
- CABA-201 is being evaluated in Phase 1/2 studies for systemic lupus erythematosus and myositis; additional indications include systemic sclerosis and generalized myasthenia gravis.
- DSG3-CAART and MuSK-CAART remain in early-stage clinical development.
- The company has not generated revenue from product sales and does not expect product revenue for several years, if at all.
Financial condition and key metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Research and development expense | $13.8 million in 2023; $8.2 million in 2022 | $38.0 million in 2023; $26.9 million in 2022 |
| General and administrative expense | $4.9 million in 2023; $3.6 million in 2022 | $13.5 million in 2023; $10.9 million in 2022 |
| Total operating expenses | $18.7 million in 2023; $11.8 million in 2022 | $51.5 million in 2023; $37.8 million in 2022 |
| Net loss | $16.4 million in 2023; $11.4 million in 2022 | $46.8 million in 2023; $37.3 million in 2022 |
| Net loss per share | $0.37 | $1.18 |
| Operating cash flow | Not separately disclosed | $(37.1) million in 2023; $(34.2) million in 2022 |
- Interest income was $2.2 million in the quarter and $4.7 million for the nine months, compared with $0.4 million and $0.6 million, respectively, in the prior-year periods.
- Cash and cash equivalents were $115.5 million at September 30, 2023, compared with $81.6 million at December 31, 2022.
- Short-term investments were $48.9 million, resulting in total cash, cash equivalents and short-term investments of $164.4 million.
- Accumulated deficit was $212.4 million; total liabilities were $12.4 million, primarily current liabilities and operating lease liabilities. The filing reports no debt financing or credit facility.
- Stockholders’ equity was $160.9 million at September 30, 2023.
Material changes versus the prior comparable period
- Quarterly research and development expense increased $5.6 million, primarily due to higher personnel, development-services, clinical-trial and manufacturing costs. The increase reflected expansion of the CABA-201 program and broader CARTA activities.
- Nine-month research and development expense increased $11.1 million. The increase included higher personnel costs, development services, licensing costs, CABA-201 clinical-trial expenses and manufacturing expenses, partly offset by completion of certain sponsored research activities in 2022.
- General and administrative expense increased $1.3 million in the quarter and $2.6 million for the nine months, primarily from increased headcount, stock-based compensation and public-company costs.
- Net loss increased $5.0 million in the quarter and $9.5 million for the nine months, despite substantially higher interest income.
- Cash increased primarily because of a May 2023 underwritten offering of 8,337,500 common shares at $12.00 per share, generating $93.8 million of net proceeds.
- The company terminated its prior 2020 ATM sales agreement in May 2023 and established a new $100 million ATM program under its 2023 shelf registration; no shares had been sold under the new program as of the filing date.
- In August 2023, the company expanded its Oxford Biomedica license and supply arrangements to include CABA-201 and entered into WuXi work orders for a dedicated manufacturing suite supporting CABA-201 and MuSK-CAART.
Guidance, outlook, commentary and risks
- Management expects research and development, general and administrative expenses and capital expenditures to increase as clinical, manufacturing and organizational activities expand.
- Management stated that existing cash, cash equivalents and short-term investments are expected to fund operations into the fourth quarter of 2025 under its current operating plan. The filing cautions that actual cash usage could be faster and that substantial additional financing will be required.
- The company expects to seek additional capital through equity offerings, debt, collaborations, licensing arrangements or other sources. Additional equity financing could dilute existing stockholders.
- Key execution risks include clinical-trial enrollment and outcomes, potential serious adverse events such as cytokine release syndrome and neurotoxicity, regulatory uncertainty for autoimmune cell therapies, manufacturing scale-up and process transfer, and reliance on Penn, WuXi, Oxford Biomedica and other third parties.
- The company is highly dependent on in-licensed intellectual property, particularly from Penn, CHOP and IASO. License termination, failure to meet diligence obligations or intellectual-property disputes could materially impair its programs.
- The company remains pre-revenue, has incurred losses in every period since inception and may never achieve profitability.
- No material litigation was reported as of September 30, 2023. Management concluded that disclosure controls were effective and that no material change in internal control over financial reporting occurred during the quarter.
Important facts for investors to verify
- Whether the projected funding runway to the fourth quarter of 2025 remains valid after subsequent clinical, manufacturing and operating developments.
- Enrollment, safety, persistence and efficacy data from the CABA-201, DesCAARTes and MusCAARTes trials, including the effects of lymphodepleting or other preconditioning regimens.
- Manufacturing capacity, process comparability, supply reliability and costs at Penn, WuXi, Oxford Biomedica and other vendors.
- The timing and terms of future financing, including use of the $100 million ATM program and potential dilution from equity issuance, options and remaining pre-funded warrants.
- Regulatory milestones and the status of INDs, fast-track designations and potential approval pathways for each indication.
- Continuing obligations and potential milestone, royalty and sublicense payments under the Penn, IASO, Oxford Biomedica, Autolus and other agreements.